Clinical Trial Update: MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for MLN8237 in ovarian, fallopian tube, or peritoneal carcinoma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Carcinoma
• Peritoneal Cancer

Drugs mentioned

• MLN8237 (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-03-27